Publications

Publications Co-Authored by Lundbeck Scientists

Our commitment to science is reflected in our track record of publications. Here are the most recent publications co-authored by Lundbeck scientists.

Article  Product Authors Publication links Year
A Randomized, Open‑Label, Multiple‑Dose, Parallel‑Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2‑Month Long‑Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder Aripiprazole
Harlin M, Yildirim M, Such P, Madera-McDonough J, Jan M, Jin N, Watkin S, Larsen F
Read publication 2023
Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: protocol for RESOLUTION – a phase 4, multi-national, randomised, double-blind, placebo-controlled study
Eptinezumab
Jensen R, Schytz H, Tassorelli C, Terwindt G, Carlsen L, Mittoux A, Osterberg O, Lipton R, Tepper S, Blumenfeld A, Lundqvist C,
Read publication 2023
Alternative Indirect Treatment Comparisons for Eptinezumab in Episodic and Chronic Migraine Prevention
Eptinezumab
Fawsitt C, Thom H, Regnier S, Lee X, Kymes S, Vase L
Read publication 2023
An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing system Brexpiprazole
Iyo M, Akiyoshi H, Sekine D, Shibasaki Y, Mamiya N
Read publication 2023
Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison
Aripiprazole
Fitzgerald H, Saklad SR, Chepke C, Harlin M, Larsen F, Chumki S, Such P, Yildirim M, Panni M, Madera-McDonough J
Read publication 2023
Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression
Vortioxetine
Montano BC, Jackson CW, Vanacore D, Weisler R
Read publication 2023
Disease-Specific Quality of Life Measures Mapped to the EQ-5D in Patients with Migraine: A Post Hoc Analysis of the DELIVER Trial
Eptinezumab
Jönsson L, Regnier SA, Kymes S, Awad SF,Talon B, Lee, XY, Goadsby P
Read publication 2023
Does ethnicity impact CYP2D6 genotype–phenotype relationships?
Vortioxetine
Frederiksen T, Areberg J, Schmidt E, Stage TB and Brøsen K
Read publication 2023
Early Clinical Experience With Eptinezumab: Results of a Retrospective Observational Study of Patient Response in the United States
Eptinezumab
Starling A, Kymes S, Asher D, Soni-Brahmbhatt S, Karnik-Henry M
Read publication 2023
Effectiveness of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: US Cohort Results From the Global RELIEVE Study
Vortioxetine
Mattingly G, Brunner E, Chrones L, Lawrence DF, Simonsen K, Ren H
Read publication 2023
Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
Vortioxetine
Cumbo E, Adair M, Åstrom DO, Christensen MC
Read publication 2023
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With Documented Prior Preventive Treatment Failures: Subgroup Analysis of the Randomized, Placebo-Controlled DELIVER Trial
Eptinezumab
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen L, Josiassen MK, Phul R, Sperling B
Read publication 2023
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures
Eptinezumab
Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B
Read publication 2023
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Eptinezumab
Starling AJ, Cowan R, Cady R
Read publication 2023
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Eptinezumab
Starling AJ, Buse D, Cowan R, Diener HC, Marmura MJ, Hirman J, Brevig T, Freeman E, Cady R
Read publication 2023
The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study
Eptinezumab
Rasmussen N, Deligianni C, Christensen C, Karlsson W, Al-Khazali H, Van de Casteele T, Granhall C, Amin F, Ashina M
Read publication 2023
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies
Vortioxetine
Mattingly GW, Necking O, Schmidt SN, Reines E, Ren H
Read publication 2023
Mental health diagnoses and services utilization vary by wage level
Vortioxetine
Sherman B, Lawrence D, Kuharic M, Chrones L, Patel S, Touya M
Read publication 2023
Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings From a Discrete Choice Experiment
Eptinezumab
Schwedt T, Martin A, Kymes S, Talon B, Lee X, Cady R, Asher D, Karnik-Henry M, Mulvihill E, Bates D, Beusterien K
Read publication 2023
Relationships Between Headache Frequency, Disability, and Disability-Related Unemployment Among Adults with Migraine
Eptinezumab
Shapiro R, Martin A, Bhardwaj S, Thomson H, Maculaitis M, Anderson C, Kymes S
Read publication 2023
Safety and effectiveness of vortioxetine for major depressive disorder: real-world evidence from a population-based study in South Korea
Vortioxetine
Moon SW, Kim JW, Kim DH, Lee KY, Reines EH, Lee M, Park YJ
Read publication 2023
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients with Bipolar I Disorder in a Randomized, Parallel-Arm, Pivotal Study
Aripiprazole
McIntyre RS, Larsen F, Madera-McDonough J, Such P, Yildirim M, Zhang Z, Harlin M
Read publication 2023
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability
Vortioxetine
Adair M, Christensen MC, Florea I, Loft H, Fagiolini A
Read publication 2023

 

Article  Product Authors Publication links Year
A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
Vortioxetine
Bose R, Hamdani SU, Minhas FA, Herr KJ
Read publication 2022
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
N/A
Meyer-Lindenberg A, Nielsen J, Such P, Lemming O, Zambori J, Buller R, von der Goltz C
Read publication 2022
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of L-Dopa-induced dyskinesia
N/A
Calabrese V, Picconi B, Heck N, Campanelli F, Natale G, Marino G, Sciaccaluga M, Ghiglieri V, Tozzi A, Anceaume E, Cuoc E, Caboche J, Conquet F, Calabresi P, Charvin D
Read publication 2022
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
N/A
Rascol O, Medori R, Baayen C, Such P, Meulien D
Read publication 2022
Activity-State Dependent Reversal of Ketamine-Induced Resting State EEG Effects by Clozapine and Naltrexone in the Freely Moving Rat
N/A
Bowman C, Richter U, Jones C, Agerskov C, Frisch Herrik K
Read publication 2022
Adherence to, and persistence of, antidepressant therapy in patients with major depressive disorder: results from a population-based study in Italy
Vortioxetine
Di Nicola M, Dell’Osso B, Peduto I, Cipelli R, Pugliese AC, Signorelli MS, Ventriglio A, Martinotti G
Read publication 2022
Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential
N/A
Wuensche T, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman E, Janssen B, Windhorst A, Jensen A, Asuni A, Bang-Andersen B, Beaino W, Dongen G, Vugts D
Read publication 2022
An app-based digit symbol substitution test for assessment of cognitive deficits in adults with major depressive disorder: evaluation study
Vortioxetine
McIntyre RS, Lipsitz O, Rodrigues NB, Subramaniapillai M, Nasri F, Lee Y, Fehnert B, King J, Chrones L, Kratiuk K, Uddin S, Rosenblat JD, Mansur RB, McCue M
Read publication 2022
Antidepressant prescription for major depressive disorder: results from a population-based study in Italy
Vortioxetine
Dell’Osso B, Di Nicola M, Cipelli R, Peduto I, Pugliese AC, Signorelli M, Ventriglio A, Martinotti G
Read publication 2022
Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink
Brexpiprazole
Tran CT, Bøg M, CollingsSL, Johnson M, Qizilbash N, Lind S, Baker RA, Jørgensen KT
Read publication 2022
Apo and ligand-bound high resolution Cryo-EM structures of the human Kv3.1 reveal a novel binding site for positive modulators
N/A
Botte M, Huber S, Bucher D, Klint J, Rodríguez D, Tagmose L, Chami M, Cheng R, Hennig M, Rahman W
Read publication 2022
Association between baseline cognitive symptoms and the subsequent presenteeism and global function in patients with major depressive disorder
Vortioxetine
Watanabe K, Marumoto T, Ge H, Moriguchi Y, Fujikawa K, Fernandez JL
Read publication 2022
Association between CYP2D6 metabolizer status and vortioxetine exposure and treatment switching: a retrospective, naturalistic cohort study using therapeutic drug monitoring data from 640 patients
Vortioxetine
Frederiksen T, Smith RL, Jukic MM, Molden E
Read publication 2022
Behavioral encoding across timescales by region-specific  dopamine dynamics
N/A
Jørgensen S,Ejdrup A, Lycas M, Posselt L, Tian L, Dreyer J, Herborg F, Sørensen A, Gether U
Read publication 2022
Changes in Acute Headache Medication Use Among Patients With Chronic Migraine: Subanalysis of PROMISE-2
Eptinezumab
Cowan RP, Marmura MJ, Diener HC, Starling A, Schim J, Hirman J, Brevig T, Cady R
Read publication 2022
Characterizing mood disorders in the AFFECT study: a large, longitudinal, and phenotypically rich genetic cohort in the US
N/A Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson C, Hinds D, 23andMe Research Team, Sullivan P, Buckholtz J, Smoller J
Read publication 2022
Characterizing Mood Disorders in the AFFECT study: A Large, Longitudinal, and Phenotypically Rich Genetic Cohort in the US
N/A
Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson C, Hinds D, 23andMe Research Team, Sullivan P, Buckholtze J, Smollerg J
Read publication 2022
Characterizing primary care for patients with major depressive disorder using electronic health records of a US-based healthcare provider
Vortioxetine
Larson S, Nemoianu A, Lawrence DF, Troup M, Gionfriddo M, Pousti B, Sun H, Riaz F, Wagner E, Chrones L, Touya M
Read publication 2022
Chronic Stress Induces Hippocampal Mitochondrial Damage in APPPS1 Model Mice and Wildtype Littermates
N/A
Clement A, Madsen M, Kastaniegaard K, Wiborg O, Asuni A, Stensballe A
Read publication 2022
Development and validation of a novel model for characterizing migraine outcomes within real-world data
Eptinezumab
Hindiyeh NA, Riskin D, Alexander K, Cady R, Kymes S
Read publication 2022
Disease progression in Multiple System Atrophy ─ Novel modelling framework and predictive factors
N/A
Kühnel L, Raket L, Åström D, Berger A-K, Helbech Hansen I, Krismer F, Wenning G, Seppi K, Poewe W, Molinuevo JL on behalf of the EMSA-SG natural history study investigators
Read publication 2022
Diseases prevalent before major depressive disorder diagnosis: an exploratory nested case–control study using health insurance-based claims data
Vortioxetine
Cho Y, Mishiro I, Akaki T, Akimoto T, Fujikawa K
Read publication 2022
Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700
N/A
Jensen K, Christoffersen C, Didriksen M, Jørgensen M
Read publication 2022
Durability of the Clinical Benefit of Droxidopa for Treatment of Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
Droxidopa
R Hauser, Gorny S, Hewitt, LA, Lindsten A, Kymes S, Favit A, Isaacson S
Read publication 2022
Early Response to Eptinezumab Indicates High Likelihood of Continued Response in Patients with Chronic Migraine
Eptinezumab
Buse DC, Winner PK, Charleston LC, Hirman J, Cady R, Brevig T
Read publication 2022
Effectiveness and safety of Vortioxetine for major depressive disorder in real-world clinical practice: results from the single-arm RELIEVE China study
Vortioxetine
Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, Guo P, Wang Z, Bai L, Reines EH, Hammer-Helmich L
Read publication 2022
Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study
Vortioxetine
Almeida SS, Christensen MC, Simonsen K, Adair M
Read publication 2022
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the RECONNECT study
Vortioxetine
Christensen MC, Schmidt S, Grande I
Read publication 2022
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice in Italy: results from the RELIEVE study
Vortioxetine
De Filippis S, Pugliese A, Christensen MC, Rosso G, Di Nicola M, Simonsen K, Ren H,
Read publication 2022
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: French cohort results from the global RELIEVE study
Vortioxetine
Polosan M, Rabbani M, Christensen MC, Simonsen K, Ren H
Read publication 2022
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study
Vortioxetine
Mattingly G, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-Helmich L
Read publication 2022
Effects of brexpiprazole on functioning in patients with schizophrenia: post hoc analysis of short- and long-term studies
Brexpiprazole
Correll CU, Shi L, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M
Read publication 2022
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
Eptinezumab
Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B
Read publication 2022
Efficacy and safety of eptinezumab for migraine prevention in patients with 2–4 prior preventive treatment failures: a randomized, double-blind, placebo-controlled, phase 3b study
Eptinezumab
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen L, Josiassen MK, Phul R, Sperling B
Read publication 2022
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
Eptinezumab
Ashina M, McAllister P, Cady R, Hirman J, Ettrup A
Read publication 2022
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness
Vortioxetine
Baldwin DS, Necking O, Schmidt SN, Ren H, Reines EH
Read publication 2022
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: a post hoc analysis of four clinical studies
Brexpiprazole
Katzman M, Therrien F, MacKenzie E, Wang F, de Jong-Laird A, Boucher M
Read publication 2022
Emotional blunting in patients with depression. Part I: clinical characteristics
Vortioxetine
Christensen MC, Ren H, Fagiolini A
Read publication 2022
Emotional blunting in patients with depression. Part II: relationship with functioning, well‑being, and quality of life
Vortioxetine
Christensen MC, Ren H, Fagiolini A
Read publication 2022
Emotional blunting in patients with depression. Part III: relationship with psychological trauma
Vortioxetine
Christensen MC, Ren H, Fagiolini A
Read publication 2022
Epidemiology and treatment utilization for Canadian patients with migraine: a literature review
Eptinezumab
Graves E, Gerber B, Berrigan P, Shaw E, Cowling T, Ladouceur MP, Bougie J,
Read publication 2022
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
Eptinezumab
Baker B, Shen V, Cady R, Ettrup A, Larsen F
Read publication 2022
Eptinezumab for migraine prevention in patients 50 years or older
Eptinezumab
Martin V, Tassorelli C, Ettrup A, Hirman J, Cady R
Read publication 2022
Eptinezumab Treatment Initiated During a Migraine Attack is Associated with Meaningful Improvement in Patient-Reported Outcome Measures: Secondary Results From the Randomized Controlled RELIEF Study
Eptinezumab
McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R
Read publication 2022
Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modelling of Brexpiprazole
Brexpiprazole
Frederiksen T, Areberg J, Raoufinia A, Schmidt E, Bjerregaard Stage T, Brøsen K
Read publication 2022
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention
Eptinezumab
Lipton R, Goadsby P, Dodick D, McGinley J, Houts C, Wirth RJ, Kymes S, Ettrup A, Østerberg O, Cady R, Ashina M, Buse D
Read publication 2022
Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews
Brexpiprazole
Therrien F, Meehan S, Weiss C, Dine J, Brown T, MacKenzie E
Read publication 2022
Further validation of the THINC-it tool and extension of the normative data set in a study of n = 10.019 typical controls
N/A
Dalby M, Annas P, Harrison JE
Read publication 2022
Health-related quality of life over 6 months in patients with major depressive disorder who started antidepressant monotherapy
Vortioxetine
Noto S, Wake M, Mishiro I, Hammer-Helmich L, Ren H, Moriguchi Y, Fujikawa K, Fernandez J
Read publication 2022
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
Eptinezumab
Martin V, Nagy J, Janelidize M, Giorgadze G, Hirman J, Cady R, Mehta L., Buse D,
Read publication 2022
Impact of depression onset and treatment on the trend of annual medical costs in Japan: an exploratory, descriptive analysis of employer-based health insurance claims data
Vortioxetine
Cho Y, Mishiro I, Fujimoto S, Nakajima T
Read publication 2022
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data
Vortioxetine
Touya M, Lawrence D, Kangethe A, Chrones L, Evangelatos T, Polson M
Read publication 2022
Indirect Meta-Analysis of Brexpiprazole Versus Aripiprazole in the Acute Treatment of Schizophrenia
Brexpiprazole
Seifritz E, Friede M, Schnitker J
Read publication 2022
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials
Eptinezumab
Anderson C, Brunner E, Cady R, Hirman J, Ogbru A, McGill L, Schim J
Read publication 2022
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
Eptinezumab
Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R
Read publication 2022
Lu AG64066 for Tourette Syndrome in adults.
N/A
Mueller-Vahl K; TBD
Read publication 2022
Measuring Dose-Related Efficacy of Eptinezumab for Migraine Prevention: Post Hoc Analysis of PROMISE-1 and PROMISE-2 Eptinezumab Apelian R, Boyle L, Hirman J, Asher D Read publication 2022
Mental healthcare resource utilization following initiation of aripiprazole 400mg long-acting injectable: a retrospective real-world study Aripiprazole Waters HC, Touya M, Wee SN, Ng M, Thadani S, Surendran S, Rentería M, Rush AJ, Patel R, Sarkar J, Fitzgerald HM, Chen M, Han X Read publication 2022
Mobile app to enhance patient activation and patient-provider communication in major depressive disorder management: collaborative, randomized controlled pilot study Vortioxetine McCue M, Blair C, Fehnert B, King J, Cormack F, Sarkey S, Eramo A, Kabir C, Khatib R, Kemp D Read publication 2022
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study Eptinezumab Cady R, Lipton R, Buse D, Josiassen MK, Lindsten A, Ettrup A Read publication 2022
Patient preference for early onset of efficacy of preventive migraine treatments Eptinezumab Ailani J, Winner P, Hartry A, Brevig T, Bøg M, Blædel Lassen A, Marsh K, Cutts K, Le Lay A Read publication 2022
Patient-centricity and sensitivity to change of the unified MSA rating scale subitems: a data-driven analysis N/A Krismer F, Seppi K, Jönsson L, Åström D, Berger A-K, Simonsen J, Wenning G,  Poewe W on behalf of EMSA-SG NHS Investigatorsa, Rasagiline-for-MSA investigatorsa Read publication 2022
Patient-Identified Burden and Unmet Needs in Patients With Cluster Headache: An Evidence-Based Qualitative Literature Review Eptinezumab Freeman E, Adair M, Beeler D, Casper R, Herman MP, Reeves D, Reinsch S Read publication 2022
Patient-reported outcome measures for life engagement in mental health: a systematic review Brexpiprazole McIntyre RS, Ismail Z, Watling CP, Weiss C, Meehan SR, Oberdhan D, Musingarimi P, Thase ME Read publication 2022
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials Eptinezumab Lipton RB, Charleston L, Tassorelli C, Brevig T, Hirman J, Cady R Read publication 2022
PET as a translational tool in drug development for Neuroscience compounds Vortioxetine Varrone A, Bundgaard C, Bang-Andersen B Read publication 2022
PET as a translational tool in drug development for Neuroscience compounds N/A Varrone A, Bundgaard C, Bang-Andersen B Read publication 2022
Polygenic heterogeneity in antidepressant treatment and placebo response Vortioxetine Nøhr AK, Forsingdal A, Moltke I, D. Howes OD, Vitezic M, Albrechtsen A, Dalby M Read publication 2022
Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia Aripiprazole Wang X, Raoufinia A, Bihorel S, Passarell J, Mallikaarjun S, Phillips L Read publication 2022
Practical advice for primary care clinicians on the safe and effective use of vortioxetine for patients with major depressive disorder (MDD) Vortioxetine Montano  B, Jackson C, Vanacore D, Weisler R Read publication 2022
Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder Vortioxetine Sumiyoshi T, Hoshino T, Mishiro I, Hammer-Helmich L, Ge H, Moriguchi Y, Fujikawa K, Fernandez J Read publication 2022
Psychometric Validation of a Patient-Reported Single-Item Assessment of “Good Day Bad Day” in a Neurogenic Orthostatic Hypotension Population Treated With Droxidopa Droxidopa François C, Kymes S, Hewitt LA, Germain N, Majewska R, Taieb V Read publication 2022
Psychometric Validation of a Patient-Reported Single-Item Assessment of “Good Day Bad Day” in a Neurogenic Orthostatic Hypotension Population Treated With Droxidopa Droxidopa Francois C, Germain N, Majewska R, Taieb V, Hewitt LA,  Kymes Read publication 2022
Rapid Resolution of Migraine Symptoms After Initiating the Preventive Treatment Eptinezumab During a Migraine Attack: Results from the Randomized RELIEF Trial Eptinezumab Ailani J, McAllister P, Winner PK Chakhava G, Josiassen MK, Lindsten A, Sperling B, Ettrup A, Cady R Read publication 2022
Readmissions, Costs, and Predictors of Time to Outpatient Follow-Up After Discharge Among Medicaid Beneficiaries Utilizing Oral versus Long-Acting Injectable Antipsychotics in Bipolar Disorder or Schizophrenia Aripiprazole Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH Read publication 2022
Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects Vortioxetine Papalexi E, Galanopoulos A, Kontis D, Markopoulou M, Balta G, Karavelas E, Panagiotidis P, Vlachos T, Ettrup A       Read publication 2022
Reduction in Migraine-Associated Burden After Eptinezumab Treatment in Patients With Chronic Migraine Eptinezumab McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A Read publication 2022
Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Recruitment and retention in a longitudinal remote measurement study N/A Matcham F, Leightley D, Siddi S, Lamers F, White KM, Annas P, de Girolamo G, Difrancesco S, Haro JM, Horsfall M, Ivan A, Lavelle G, Li Q, Lombardini F, Mohr DC, Narayan V, Oetzmann C, Penninx BWJH, Simblett S, Wykes T, PAB member, Brasen C, Myin-Germeys I, Rintala A, Dobson R, Folarin A, Ranjan Y, Cummins N, Manyakov N, Vairavan S, Hotopf M, on behalf of the RADAR-CNS consortium Read publication 2022
Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD) Vortioxetine Papalexi E, Galanopoulos A, Roukas D, Argyropoulos I, Michopoulos I, Douzenis A, Gkolia I, Fotiadis P, Kontis, Zervas IM Read publication 2022
Risk of major depressive disorder in adolescent and young adult cancer patients in Japan Vortioxetine Akechi T, Mishiro I, Fujimoto S Read publication 2022
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies Eptinezumab Pozo-Rosich P, Dodick D, Ettrup A, Hirman J, Cady R Read publication 2022
The Economic Burden of Post-Traumatic Stress Disorder in the United States from a Societal Perspective Brexpiprazole Davis L, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle C Read publication 2022
The effect of combined dexmedetomidine and  isoflurane anaesthesia on visually evoked  responses in rats – an electrophysiological study N/A Østergaard F, Skoven CS, Laursen B, Dyrby T, Wade A Read publication 2022
The effect of combined dexmedetomidine and isoflurane anaesthesia on visually evoked responses in rats – an electrophysiological study N/A Østergaard F, Laursen B, Christensen K et al Read publication 2022
The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study Vortioxetine Christensen MC, Adair M, Loft H, McIntyre R Read publication 2022
The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach Aripiprazole Correll C, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister T, Brown D, Clarke C, Hassoun Y Read publication 2022
Therapeutic potential of vortioxetine for anhedonia-like symptoms in depression: a post hoc analysis of data from a clinical trial conducted in Japan Vortioxetine Watanabe K, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Inoue T Read publication 2022
Townsend et al. Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis Brexpiprazole Townsend M, Houle C, Mose TN, Pareja K, Waters H, Brubaker M, Buchanan-Hughes A, Worthington E, Pritchett D   Read publication 2022
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study Brexpiprazole Hishimoto A, Yasui-Fukukori N, Sekine D, Matsukawa M, Yamada S Read publication 2022
Validation and functional relevance of the short form of the perceived deficits questionnaire for depression for Japanese patients with major depressive disorder Vortioxetine Sumiyoshi T, Uchida H, Watanabe K, Oosawa M, Ren H, Moriguchi Y, Fujikawa K, Fernandez J Read publication 2022
Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study Vortioxetine Thase M, Jacobsen P, Hanson E, Xu R, Tolkoff M, Murthy V Read publication 2022
Vortioxetine for major depressive disorder in adolescents: 12-week randomized, placebo-controlled, fluoxetine-referenced, fixed-dose study Vortioxetine Findling RL, DelBello M, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M Read publication 2022

 

Article  Product Authors Publication links Year Journal
A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with Major Depression Disorder Vortioxetine Nøhr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A Read publication 2021 Neuropsychopharmacology
A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once-Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Schizophrenia Aripiprazole Such P, Bøg M, Kabra M, Jørgensen KT, de Jong-Laird AC  Read publication 2021 The Primary Care Companion for CNS Disorders
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess patient support program Vortioxetine Lawrence D, Manjelievskaia J, Chrones L, McCue M, Touya M Read publication 2021 Current Medical Research & Opinion
Agitation in dementia: real-world impact and burden on patients and the healthcare
system
Brexpiprazole Jones E, Aigbogun MS, Pike J, Berry M, Houle CR, Husbands J Read publication 2021 Journal of Alzheimer's Disease
An alternative start regimen with aripiprazole once-monthly in patients with
schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection
Aripiprazole Wang Y, Wang X, Harlin M, Larsen F, Panni M, Yildirim M, Madera J, Forbes A, Mustafa N, Ruiz-White I, Raoufinia A Read publication 2021 Current Medical Research & Opinion
An integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modelling method to evaluate treatments for adults with schizophrenia Aripiprazole Piena M, Houwing N, Kraan C, Wang X, Waters H, Duffy R, Mallikaarjun S, Bennison C Read publication 2021 PharmacoEconomics
An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy
participants
Brexpiprazole Dean F. Wong; Suresh Malikaarjun; Arash Raoufinia; Patricia Bricmont; James R. Brašić; Robert D. McQuade; Robert A. Forbes; Tetsuro Kikuchi; Hiroto Kuwabara Read publication 2021 European Journal of Clinical Pharmacology
Anti-Aβ antibody Aducanumab regulates the proteome of senile plaques and closely
surrounding tissue in a transgenic mouse model of Alzheimer’s disease
N/A Bastrup J, Hansen K, Poulsen T, Kastaniegaard K, Asuni AA, Christensen S, Belling D, Stensballe A, Volbracht C Read publication 2021 Journal of Alzheimer's Disease
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: Associations with clinical and treatment outcomes in the AtWoRC
Study
Vortioxetine Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G Read publication 2021 Therapeutic Advances in Psychopharmacology
Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations? Experiences from a study of anti-depressants in healthy volunteers Vortioxetine Larsen KG, Areberg J, Åström DO Read publication 2021 Clinical Trials
Branning et al. Mental Illness Disclosure in the Workplace: An Opportunity for Improvement. American Health and Drug Benefits Brexpiprazole Branning G; Waters HC; Houle CR; Worthy S; Fink B; Hayes K   Read publication 2021 -
Brexpiprazole blocks Posttraumatic stress disorder-like memory and promotes normal fear memory Brexpiprazole Ducourneau E-G, Guette C, Perrot D, Mondesir M, Mombereau C, Arnt J, Desmedt A, Piazza P-V Read publication 2021 Molecular Psychiatry
Cardiovascular Outcomes in Adults With Migraine Treated With Eptinezumab for Migraine Prevention: Pooled Data From Four Double-Blind, Randomized, Placebo-Controlled Studies Eptinezumab Smith T, Spierings E, Cady R, Hirman J, Ettrup A, Shen V. Read publication
2021 -
Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent Vortioxetine Bernhard T Baune, Falkai P Read publication 2021 Australian and New Zealand Journal of Psychiatry
Characterization of the changes in supine blood pressure with long-term use of droxidopa in patients with neurogenic orthostatic hypotension Droxidopa Hewitt LA, Lindsten A, Gorny S, Karnik-Henry M, Kymes S, Favit A Read publication 2021 -
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: an open-label,
flexible-dose, exploratory substudy
Brexpiprazole Krystal AD, Mittoux A, Lindsten A, Baker RA Read publication 2021 Journal of Affective Disorders
Clinical immunogenicity evaluation of Eptinezumab, a therapeutic humanized monoclonal antibody for the preventive treatment of migraine Eptinezumab Pederson S, Biondi D, Allan B, Cady R, Schaeffler B, Baker B, Latham J Read publication 2021 Frontiers in Immunology
Design and Synthesis of Pyrrolo[2,3 d]pyrimidine-derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors using a Checkpoint Kinase 1 (CHK1)-derived
Crystallographic Surrogate
N/A Williamson D, Smith G, Mikkelsen G, Jensen T, Acheson-Dossang P, Badolo L, Bedford S, Chell V, Jen Chen I, Dokurno P, Hentzer M, Newland S, Ray S, Shaw T, Surgenor A, Terry L, Wang Y, Christensen K Read publication 2021 Journal of Medicinal Chemistry
Droxidopa persistence in neurogenic orthostatic hypotension may be affected by titration approach Droxidopa F Amjad, B Polenchar, A Favit Read publication 2021 International Journal of General Medicine
Early improvement with vortioxetine predicts response and remission: a post hoc analysis of data from a clinical trial conducted in Japan Vortioxetine Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K Read publication 2021 -
Effectiveness of vortioxetine on emotional blunting in patients with major depressive
disorder with inadequate response to SSRI/SNRI treatment
Vortioxetine Fagiolini A, Florea I, Loft H, Christensen MC Read publication 2021 Journal of Affective Disorders
Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews Brexpiprazole Weiss C, Meehan SR, Brown TM, Gupta C, Mørup MF, Thase ME, McIntyre RS, Ismail Z Read publication 2021 -
Effects of brexpiprazole across symptom domains in patients with schizophrenia: post hoc analysis of short- and long-term studies Brexpiprazole Marder S, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N Read publication 2021 Schizophrenia Bulletin
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial Eptinezumab Winner P, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen MK, Lindsten A, Mehta L, Cady R Read publication 2021 JAMA: Journal of the American Medical Association
Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder Vortioxetine McIntyre R, Loft H, Christensen MC Read publication 2021 Neuropsychiatric Disease and Treatment
Establishment of a Human Induced Pluripotent Stem Cell Neuronal Model for Identification of Modulators of α-Synuclein Levels and Aggregation N/A Vajhøj C, Schmid B, Bousset L, Melki R, Fog K, Holst B, Stummann TC Read publication 2021 -
Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review Brexpiprazole Brockbank J, Krause T, Moss E, Milthers Pedersen A, Frank Mørup M, Ahdesmäki O, Vaughan J, Brodtkorb T-H Read publication 2021 Health and Quality of Life Outcomes
Impact of Agitation in Long-Term Care Residents with Dementia in the United States Brexpiprazole Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G Read publication 2021 International Journal of Geriatric Psychiatry
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole Brexpiprazole Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Nemoto H, Hashizume K, Ohzone Y, Amunom I, Torii M, Umehara K, Kashiyama E, Takeuchi K  Read publication 2021 Xenobiotica
In vivo and in vitro pharmacokinetic characterization of a novel serotonin-dopamine activity modulator brexpiprazole and a main metabolite in rat, monkey and
human
Brexpiprazole Sasabe H, Koga T, Furukawa M, Matsunaga M, Kaneko Y, Koyama N, Hirao Y, Akazawa H, Kawabata M, Kashiyama E, Takeuchi K. Read publication 2021 Xenobiotica
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis Vortioxetine Kangethe A, Lawrence DF, Touya M, Chrones L, Polson M, Evangelatos T Read publication 2021 BMC Health Services Research
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial Eptinezumab Kudrow D, Cady R, Allan B, Pederson S, Hirman J, Mehta L., Schaeffler B. Read publication 2021 BMC Neurology
Management of Neurogenic Orthostatic Hypotension in Neurodegenerative Disorders: A Collaboration Between Cardiology and Neurology Droxidopa F Amjad, S Beinart Read publication 2021 Neurology and Therapy
Management Strategies for Comorbid Supine Hypertension in Patients With Neurogenic Orthostatic Hypotension Droxidopa Isaacson S, Dashtipour K, Mehdirad A, Peltier A Read publication 2021 Current Neurology and Neuroscience Reports
Monoacylglycerol lipase inhibition in Tourette syndrome. A 12-week randomized, placebo-controlled, study with Lu AG06466 N/A Kirsten R. Müller-Vahl, Carolin Fremer, Chan Beals, Jelena Ivkovic, Henrik Loft and Christoph Schindler Read publication 2021 -
New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience
Data in FDA Drug Approval Packages and Product Labels
N/A Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Blaedel Lassen A, Vinther Morant A Read publication 2021 Therapeutic Innovation & Regulatory Science
Nonclinical safety evaluation, pharmacokinetics and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies N/A Fjord-Larsen L, Thougaard A, Wegener KM, Christensen J, Larsen F, Schrøder-Hansen LM, Kaarde M, Ditlevsen D Read publication 2021 -
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with
Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
Aripiprazole Such P, Olivares JM, Arias L, Berg MT, Madera J  Read publication 2021 Neuropsychiatric Disease and Treatment
Patient and physician perspectives of depressive symptoms and expectations for
treatment outcome: results from a web-based survey
Vortioxetine Ishigooka J, Hoshino T, Imai T,Yoshida H, Ono M, Ota M, Moriguchi Y, Fujikawa K, Shintani A, Fernandez J Read publication 2021 Neuropsychiatric Disease and Treatment
Patient expectations and experience of the early phases of antidepressant therapy for
major depressive disorder: A qualitative study
Vortioxetine Baune BT, Florea I, Ebert B, Touya M, Ettrup A, Hadi M, Ren H  Read publication 2021 Neuropsychiatric Disease and Treatment
Patient-Identified Most Bothersome Symptom in Preventive Migraine Treatment With Eptinezumab: A Novel Patient Centered Outcome Eptinezumab Lipton R, Dodick D, Ailani J, McGill L, Hirman J, Cady R Read publication 2021 Headache: The Journal of Head and Face Pain
Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study N/A Kühnel L, Bouteloup V, Lespinasse J, Chêne G, Dufouil C, Raket LL Read publication 2021 -
Phosphodiesterase type 1 inhibition Alters medial prefrontal cortical activity and
reward-driven behaviour and Partially reverses neurophysiological deficits in
the rat phencyclidine model of schizophrenia
N/A Hayes J, Laursen B, Eneberg E, Kehler J, Rasmussen L, Langgard M, Bastlund J,
Gerdjikov T
Read publication 2021 Neuropsychopharmacology
Pooled analysis of safety information of clinical trials of vortioxetine including Japanese patients with major depressive disorder Vortioxetine Osawa M, Nakajima T, Fujimoto S, Ogino Y, Moriguchi Y, Takeshi I Read publication 2021 -
Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden Brexpiprazole Jørgensen KT, Bøg M,Kabra M, Simonsen J, Adair M, Jönsson L   Read publication 2021 -
Predictors and trajectories of treatment response to SSRIs in patients suffering from
PTSD
Brexpiprazole Anne Krogh Nøhr, Hans Eriksson, Mary Hobart, Ida Moltke, Raimund Buller, Anders Albrechtsen, Stinus Lindgreen Read publication 2021 Psychiatry Research
Predictors of persistence in patients with schizophrenia treated with aripiprazole
once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
Aripiprazole Olivares JM, González-Pinto A, Páramo M Read publication 2021 European Psychiatry
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review Brexpiprazole Schein J, Houle CR, Urganus AL, Jones E, Pike J, Husbands J, Willey CJ Read publication 2021 -
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache Eptinezumab Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R Read publication 2021 Headache: The Journal of Head and Face Pain
Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through
population pharmacokinetic analysis of vortioxetine
Vortioxetine Frederiksen T, Areberg J, Schmidt E, Stage TB, Brosen K Read publication 2021 Clinical Pharmacology & Therapeutics
Redefining Expectations for Migraine Prevention Eptinezumab Cady R, Gottschalk C, Pavlovic J Read publication 2021 US Neurology
Relationship of subjective cognitive impairment with psychosocial function and relapse of depressive symptoms in patients with major depressive disorder: analysis of
longitudinal data from PERFORM-J
Vortioxetine Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J Read publication 2021 Neuropsychiatric Disease and Treatment
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials Eptinezumab Smith T, Spierings E , Cady R, Hirman J, Schaeffler B, Werther S, Shen V, Spierling B, Brevig T, Josiassen M,  Brunner E, Mehta L, Honeywell L Read publication 2021 The Journal of Headache and Pain
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: a post-hoc analysis of a long-term open label study Brexpiprazole Ishigooka J, Inada K, Niidome K, Aoki K, Kijima Y, Iwashita S, Yamada S Read publication 2021 Human Psychopharmacology: Clinical and Experimental, Psychiatry and Clinical
Neurosciences
Schein et al. Prevalence of post-traumatic stress disorder in the United States: A systematic literature review Brexpiprazole Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, Guerin A, Lefebvre P, Davis LL Read publication 2021 Current Medical Research & Opinion
Simultaneous Modelling of Alzheimer’s Disease Progression via Multiple Cognitive Scales N/A Kühnel L, Berger A-K, Markussen B,  Raket L Read publication 2021 Statistics in Medicine
Systemic administration of Ivabradine, an HCN channel inhibitor, blocks spontaneous absence seizures N/A Iacone Y, Morais T, David F, Delicata F, Parri R, Weisser J, Bundgaard C, Vestergaard Klewe I, Thomsen M, Crunelli V, Lőrincz M Read publication 2021 Epilepsia
The Eptinezumab:CGRP Complex Structure: The Role  of Conformational Changes in Binding Stabilization Eptinezumab Laurent D, Scalley Kim M, Olland A, White A, Misura K,   Read publication 2021 -
Therapeutic potential of vortioxetine for anxious depression: a post hoc analysis of data from a clinical trial conducted in Japan Vortioxetine Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida I, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K Read publication 2021 -
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients Eptinezumab Baker B, Schaeffler B, Hirman J, Hompesch M, Peterson S, Smith J Read publication 2021 Endocrinology, Diabetes & Metabolism
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection Aripiprazole Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M Read publication 2021 Neuropsychiatric Disease and Treatment
Two randomized, placebo-controlled double-blind trials and one open-label long-term trial of brexpiprazole for the acute treatment of bipolar mania Brexpiprazole Eduard Vieta, Gary Sachs, Denise Chang, Johan Hellsten, Claudette Brewer, Tim Peters Strickland, Nanco Hefting Read publication 2021 Journal of Psychopharmacology
Using the goal attainment scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open label, multicenter study Vortioxetine McCue M, Sarkey S, Eramo A, François C, Parikh SV Read publication 2021 BMC Psychiatry
Validation of a population pharmacokinetic model of vortioxetine using therapeutic drug monitoring data Vortioxetine Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E   Read publication 2021 -
Validation of the oxford depression questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting Vortioxetine Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin G Read publication 2021 Journal of Affective Disorders Reports
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety and optimal timing of dose adjustment Vortioxetine Christensen MC, McIntyre RS, Florea I, Loft H, Fagiolini A Read publication 2021 CNS Spectrums

 

Article  Product Authors Publication links Year Journal
A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study Vortioxetine Jacobsen P, Zhong W, Xu R, Nomikos G Read publication 2020 Journal of Affective Disorders
A PET Occupancy Study of Brexpiprazole at Dopamine D2 and D3 Receptors, Serotonin 5-HT1A and 5-HT2A Receptors, and Serotonin Reuptake Transporters in Subjects With Schizophrenia Brexpiprazole Girgis R, Abi-Dargham A, Forbes, A, Slifstein M Read publication 2020 Neuropsychopharmacology
A Questionnaire-Based Evaluation of the Attitude of European Physicians towards the Use of Antipsychotic Long-Acting Injectables Aripiprazole Heres S, Patel M, Bent-Ennakhil N, Sapin C, di Nicola S Read publication 2020 BMC Psychiatry,European Neuropsychopharmacology
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder Vortioxetine Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I Read publication 2020 Rinsho Yakuri (Japanese Journal of Clinical Pharmacology)
Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction Droxidopa Mehdirad A, Khemani P Read publication 2020 Cardiology in Review
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram Vortioxetine Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton  Read publication 2020 CNS Spectrums
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine Eptinezumab Houts, C, Wirth R, McGinley J, Cady R, Lipton R, Read publication 2020 Headache: The Journal of Head and Face Pain
Effect of brexpiprazole on impulsivity in schizophrenia: a task-based functional magnetic resonance imaging study Brexpiprazole van Erp TGM, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG Read publication 2020 Psychiatry Research: Neuroimaging 
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma Vortioxetine Christensen MC, Florea I, Loft H, McIntyre RS Read publication 2020 Journal of Affective Disorders
Efficacy, Tolerability, and Safety of Eptinezumab in Patients with a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2 Eptinezumab Diener HC, Marmura M, Tepper S, Cowan R, Starling A, Diamond M, Hirman J, Mehta L, Brevig T, Sperling B, Cady R Read publication 2020 Headache: The Journal of Head and Face Pain
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing Eptinezumab Dodick D, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S   2020  
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 study Eptinezumab Silberstein S, Diamond M, Hindiyeh N, Biondi D, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J, Read publication 2020 The Journal of Headache and Pain
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study Eptinezumab Smith T, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S,Smith J, Schaeffler B, Read publication 2020 Clinical Therapeutics
Eptinezumab in episodic migraine: The randomized, double-blind, placebo-controlled PROMISE-1 study Eptinezumab Ashina M, Saper J, Cady R, Schaeffler B, Biondi D, Hirman J, Pederson S, Allan B, Smith J Read publication 2020 Cephalalgia
Impact of atypical antipsychotics as adjunctive therapy on psychiatric cost and utilization in patients with major depressive disorder Brexpiprazole  Yan T, Greene M, Chang E, Houle C, Tarbox M, Broder MS Read publication 2020 ClinicoEconomics and Outcomes Research
Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT study Vortioxetine Wang G, Tan KHX, Ren H, Hammer-Helmich L Read publication 2020 Neuropsychiatric Disease and Treatment
Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study Vortioxetine Chokka P, Bougie J, Tvistholm AH, Clerzius G, Ettrup A Read publication 2020 Journal of Occupational and Environmental Medicine
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 7-day randomized, double-blind, placebo-controlled exploratory study Vortioxetine Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I Read publication 2020 International Clinical Psychopharmacology
Neurobiology of TRS: Research Roadmap Lu AF35700 Kane J, Potkin S, Correll C, Agid O, Olfson M, Lindenmayer JP, Marder S, Howes O Read publication 2020 npj Schizophrenia
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls Droxidopa LeWitt P, Kymes S, Hauser R Read publication 2020 Aging and Disease
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine Droxidopa Mobarek S Read publication 2020  
Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide Eptinezumab Garcia-Martinez L, Raport C, Ojala E, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham J Read publication 2020 Journal of Pharmacology and Experimental Therapeutics
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine Eptinezumab Baker B, Schaeffler B, Beliveau M, Rubets I   2020 Pharmacology Research & Perspectives
Post hoc analysis of a randomized, placebo-controlled, active-reference 6-week study of brexpiprazole in patients with acute schizophrenia Brexpiprazole Marder SR, Eriksson H, Zhao Y, Hobart M Read publication 2020 Acta Neuropsychiatrica
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study Brexpiprazole Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S   2020  
PROMISE–2: Efficacy and safety of eptinezumab in patients with chronic migraine Eptinezumab Lipton R, Goadsby P, Smith J, Schaeffler B, Biondi D,  Hirman J, Pederson S, Allan B, Cady R Read publication 2020 Neurology
Psychiatric Cost in Patients with Schizophrenia Treated with Oral Atypical Antipsychotic Therapy Brexpiprazole 
Yan T, Greene M, Chang E, Houle C, Waters HC, Tarbox M, Broder MS Read publication 2020 Clinical Therapeutics
Real-World Droxidopa or Midodrine Treatment Persistence  in Patients With Neurogenic Orthostatic Hypotension  or Orthostatic Hypotension Droxidopa Kymes S, Jackson K, Sullivan, C, Raj S Read publication 2020 Autonomic Neuroscience: Basic & Clinical
Real-World Patient Experience with Sexual Dysfunction and Antidepressant use in Depressed Patients: A Cross-Sectional Survey Study Vortioxetine Paula L. Jacobsen, Eileen M. Thorley, Christopher Curran, Emil Chiauzzi Read publication 2020 Neurology, Psychiatry and Brain Research
Reliability and validity of the 6‑item Headache Impact Test in chronic migraine from the PROMISE‑2 study Eptinezumab Houts CR, McGinley JS, C, Wirth RJ, Cady R, Lipton RB, Read publication 2020 Quality of Life Research
Risk of major depressive disorder in Japanese cancer patients: A matched cohort study using employer-based health insurance claims data Vortioxetine Akechi T, Mishiro I, Fujimoto S, Murase K Read publication 2020 Psycho-Oncology
Risk of major depressive disorder in spouses of cancer patients in Japan: a cohort study using health-insurance based claims data Vortioxetine Akechi T, Mishiro I, Fujimoto S, Murase K Read publication 2020 Psycho-Oncology
Successfully treated patients with vortioxetine versus venlafaxine: A simplified cost-effectiveness analysis in Asian patients with major depressive disorder Vortioxetine Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen H-LF, Ettrup A Read publication 2020 Current Medical Research & Opinion
Symptoms of major depressive disorder and psychosocial functioning in the different phases of the disease: does the perspective of patients and healthcare providers differ? Vortioxetine Christensen MC, Wong J, Baune BT Read publication 2020 Frontiers in Psychiatry
The Impact of the Food and Drug Administration Antipsychotic Drug Boxed Warning on Psychiatric Medication Use, Health Events, and Quality of Life in Elderly Dementia Patients Brexpiprazole  Annalisa Rubino, Myrlene Sanon, Michael Ganz, Alex Simpson, Miram Fenton, Sumit Verma, Ann Hartry, Ross Baker, Ruth Duffy, Keva Gwin, Howard Fillit  Read publication 2020 JAMA Network Open
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: A report on global assessment of functioning and the WHO wellbeing index Aripiprazole Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K
Read publication 2020 BMC Psychiatry
Treatment of major depressive disorder in Japanese patients with cancer: a matched cohort study using employer-based health insurance claims data Vortioxetine Akechi T, Fujimoto S, Mishiro I, Murase K
Read publication 2020 Clinical Drug Investigation
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder Vortioxetine Murthy V, Xu R, Zhong W, Harvey P Read publication 2020 Journal of Affective Disorders

 

Article  Product Authors Publication links Year Journal
6-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
Droxidopa Francois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla C, Kymes S, Yue B Read publication 2019 Movement Disorders Clinical Practice
A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder Brexpiprazole  Hobart M, Zhang P, Brewer C, Hefting N Read publication 2019 Journal of Clinical Psychopharmacology
A new principal stratum estimand investigating the treatment effect in patients who would comply, if treated with a specific treatment Brexpiprazole  Groes Larsen K, Krog Josiassen M Read publication 2019 Statistics in Biopharmaceutical Research
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder Vortioxetine Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I Read publication 2019 Psychiatry and Clinical Neurosciences
A Systematic Literature Review Identifying Associations Between Outcomes and Quality of Life (QoL) or Health Care Resource Utilisation (HCRU) in Schizophrenia Lu AF35700 Germain N, Weatherall J, Kymes S, Löf E, Jakubowska A, François C Read publication 2019 Journal of Medical Economics
Adapting the goal attainment approach for major depressive disorder Vortioxetine McCue M, Parikh S, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Lind B, Francois C Read publication 2019 Neurology and Therapy
Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course Brexpiprazole  Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, Hammer-Helmich L, Sanon Aigbogun M Read publication 2019 International Psychogeriatrics 
Anti-tau antibody-mediated clearance in mouse microglia cultures requires Fcγ-receptor interaction and functional lysosomes AF87908 Tau Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT Read publication 2019 Scientific Reports
Assessment of current clinical practices for major depression in Japan using a web-based questionnaire Vortioxetine Hori H, Kentaro Y Read publication 2019 Neuropsychiatric Disease and Treatment
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats Brexpiprazole  Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H Kurahashi N, Kikuchi T, Futamura T Read publication 2019 Neuropsychopharmacology Reports
Burden of Care for Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes and Perceptions Lu AF35700 Velligan D, Brain C, Bouérat Duvold L, Agid O, Read publication 2019 Frontiers in Psychiatry
Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine Vortioxetine

Lachaine J, Beauchemin C, Bibeau J,

Patenaude J, Chokka P, Proulx J, Bougie J 

Read publication 2019 CNS Spectrums
Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results From a Survey of 204 US Psychiatrists Lu AF35700 Correll CU, Brevig T, Brain C Read publication 2019 BMC Psychiatry
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia Lu AF35700 Agid O, Baldwin M, Correll C, Howes O, Kane J, Lindenmayer JP, Marder S, Olfson M, Potkin S Read publication 2019 Journal of Clinical Psychiatry
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram Vortioxetine Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton  Read publication 2019 CNS Spectrums
Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China Vortioxetine Wang G, Si T-M, Li L-J, Fang Y-R, Wang C-X, Wang L-N, Tan K H X, Ettrup A; Eriksen F H-L, Luo S, Ge L Read publication 2019 Neuropsychiatric Disease and Treatment
Comparisons of Global Tests on Intersection Hypotheses and Their Application in Matched Parallel Gatekeeping Procedures Brexpiprazole  Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G Read publication 2019 Journal of Biopharmaceutical Statistics
Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases Vortioxetine Touya M, Lamy FX, Tanaescu A, Saragoussi D, Francois C, Wade A, Llorca PM, Lancon C, Falissard B Read publication 2019 Journal of Market Access & Health Policy
Development of a Classifier to Identify Patients with Probable Lennox–Gastaut Syndrome in Health Insurance Claims Databases Via Random Forest Methodology Clobazam Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J Read publication 2019 Current Medical Research & Opinion
Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression Vortioxetine Baune B, Christensen MC Read publication 2019 Frontiers in Psychiatry
Drug-Drug Interactions With Concomitant Clobazam and Cannabidiol Usage in Refractory Seizures Clobazam Tolbert D, Klein P, Gidal B Read publication 2019 Epilepsy & Behavior 
Early Initiation of Long-Acting Injectable Antipsychotic Treatment is Associated with Lower Hospitalization Rates and Healthcare Costs in Patients with Schizophrenia: Real-World Evidence From US Claims Data Aripiprazole Munday J, Broder MS, Chang E, Hartry A, Yan TJ, Greene M
Read publication
2019 Current Medical Research & Opinion
Economic burden of relapse/recurrence in patients with major depressive disorder Vortioxetine Gauthier G, Mucha L, Shi S, Guerin A Read publication 2019 Journal of Drug Assessment
Effect of brexpiprazole on agitation and hostility in patients with acute schizophrenia Brexpiprazole  Citrome L, Ouyang J, Meehan SR, Baker RA, Weiss C Read publication 2019 Journal of Clinical Psychopharmacology
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain Vortioxetine Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ Read publication 2019 Neuropsychopharmacology
Effects of vortioxetine and escitalopram on electroencephalographic recordings – A randomized, crossover trial in healthy males Vortioxetine Nissen TD, Laursen B, Viardot G, l´Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM Read publication 2019 Neuroscience
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis Vortioxetine Jacobson W, Harvey P, Zhong W, Nomikos G, Olsen CK, Christensen M Read publication 2019 Current Medical Research & Opinion
Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies Brexpiprazole  Thase M, Hobart M, Zhang P, Weiss C, Meehan SR Read publication 2019 Expert Opinion on Pharmacotherapy
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials Brexpiprazole  Grossberg G, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade R, Cummings J Read publication 2019 American Journal of Geriatric Psychiatry
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma Vortioxetine Christensen MC, Florea I, Loft H, McIntyre RS Read publication 2019 Journal of Affective Disorders
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial Eptinezumab Dodick DW, Lipton RB, Silberstein S, Goadsby P4, Biondi D, Hirman J, Cady R, Smith J Read publication 2019 Cephalalgia
Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists Lu AF35700 Correll CU, Brevig T, Brain C Read publication 2019 Neuropsychiatric Disease and Treatment
Health-related quality of life outcomes, economic burden and cost associated among diagnosed and undiagnosed depression patients in Japan Vortioxetine Yamabe K, Liebert R, Flores N Read publication 2019 ClinicoEconomics and Outcomes Research
Identifying and Characterizing Treatment-Resistant Schizophrenia in Observational Database Studies Lu AF35700 Jonsson L, Simonsen J, Brain C, Kymes S, Watson L Read publication 2019 International Journal of Methods in Psychiatric Research
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study Vortioxetine Vieta E, Florea I, Schmidt S N, Areberg J, Ettrup A Read publication 2019 International Clinical Psychopharmacology
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study Vortioxetine Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A Read publication 2019 CNS Spectrums
Management of Coexistent Neurogenic  Orthostatic Hypotension and Supine Hypertension Droxidopa Cannom D Read publication 2019 Journal of Clinical Hypertension
Management of Depression in Adolescents in Japan Escitalopram Saito T, Reines E, Florea I, Dalsgaard M Read publication 2019 Journal of Child and Adolescent Psychopharmacology
Medication adherence, health service use, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment Brexpiprazole  Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I Read publication 2019 Clinical Therapeutics
Neurogenic Orthostatic Hypotension: A Nonmotor Symptom of Parkinson Disease Droxidopa Low P, Cutsforth-Gregory J Read publication 2019 Neurology and Therapy
Open-label, Multicenter, Phase 3 Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease Idalopirdine Frölich L, Alireza A, Ballard C, Tariot P, Molinuevo JL, Boneva N, Geist M, Raket L, Cummings J  Read publication 2019 Journal of Alzheimer's Disease
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls Droxidopa LeWitt P, Kymes S, Hauser R Read publication 2019 Aging and Disease
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial Vortioxetine Jacobsen P, Zhong W, Nomikos G, Clayton A Read publication 2019 The Journal of Sexual Medicine
Patient attitudes towards and goals for MDD treatment: A survey study Vortioxetine McNaughton E, Granskie J, Curran C, Opler M, Sarkey S, Mucha L, Eramo A, Francois C, Webber-Lind B, McCue M Read publication 2019 Patient Preference and Adherence
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study Vortioxetine Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG Read publication 2019 Neuropsychiatric Disease and Treatment
Pharmacokinetics and safety of vortioxetine in the Chinese population Vortioxetine Miao J, Wang G, Hou J, Areberg J, Zhao Y,  Højer AM, Ettrup A Read publication 2019 Advances in Therapy
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide Eptinezumab Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF Read publication 2019 Journal of Pharmacology and Experimental Therapeutics
Pharmacometrics of Clobazam in Pediatrics: Prediction of Effective Clobazam Doses for Dravet Syndrome Clobazam Tolbert D, Chu H-M, Ette EI Read publication 2019 Epilepsy Research
Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis Vortioxetine Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F Read publication 2019 British Journal of Clinical Pharmacology
Psychometric validation of Japanese version of Alcohol Quality of Life Scale (AQoLS) in the treatment of patients with alcohol use disorder – a non-interventional, prospective, longitudinal, multi-site cohort study Nalmefene Higuchi S, Moriguchi Y, Tan KHX Read publication 2019 Quality of Life Research
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study Aripiprazole Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A Read publication 2019 BMC Psychiatry
Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross sectional analysis of baseline data from PERFORM-J Vortioxetine Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan K, Hammer-Helmich L, Fernandez J Read publication 2019 Journal of Affective Disorders
Results and validation of an index to measure health state of patients with depression in automated healthcare databases Vortioxetine Lamy FX, Falissard B, Francois C, Lancon C, Llorca PM, Tanaescu A, Touya M, Verpillat P, Wade A, Saragoussi D Read publication 2019 Journal of Market Access & Health Policy
Results of a Real-World Study of Vortioxetine in Patients with Major Depressive Disorder in South East Asia (REVIDA): Subgroup Analysis of Malaysian Patients Vortioxetine Chin CN, Azhar, Au YKC, Chong MSwee Woon, Yen TH, Yeoh BBD, Yap CH, Ku RKA, Keira JH Read publication 2019 Malaysian Journal of Psychiatry
Role of Nurses and Nurse Practitioners in the Recognition, Diagnosis, and Management of Neurogenic Orthostatic Hypotension Droxidopa Biswas D, Karabin B, Turner D Read publication 2019 International Journal of General Medicine
Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. Vortioxetine Mahableshwarkar A, Jacobsen P, Affinito J, Reines E, Xu J, Nomikos G Read publication 2019 CNS Spectrums
Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies Aripiprazole Madera JJ, Such P, Zhao C, Baker RA Read publication 2019 Neuropsychiatric Disease and Treatment
The effect of aripiprazole once monthly on personal and social functioning: Post hoc analyses of acute and long-term studies Aripiprazole Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ Read publication 2019 Neuropsychiatric Disease and Treatment
The patient perspective on cognitive symptoms in major depressive disorder: a retrospective database and prospective survey analysis Vortioxetine Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D Read publication 2019 Journal of Participatory Medicine
Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine Vortioxetine Nierenberg AA, Loft H, Olsen CK Read publication 2019 Journal of Affective Disorders
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient With Cardiovascular Disease and Parkinson Disease: A Case Report Droxidopa McCullough P Read publication 2019 Cardiology and Therapy
Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis Brexpiprazole  Sanon Aigbogun M, Stellhorn R, Hartry A, Baker RA, Fillit H Read publication 2019 BMC Neurology
Use of Droxidopa for the Long-Term Treatment of Neurogenic Orthostatic Hypotension Droxidopa Hewitt LA, Raj S Read publication 2019 European Heart Journal
Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment Aripiprazole Madera JJ, Such P, Zhang P, Baker RA, Grande I Read publication 2019 Neuropsychiatric Disease and Treatment
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder Vortioxetine Murthy V, Xu R, Zhong W, Harvey P Read publication 2019 Journal of Affective Disorders
Utility of Autonomic Testing for the Efficient Diagnosis and Effective Pharmacologic Management of Neurogenic Orthostatic Hypotension Droxidopa Suleman, A; Bin Alam, S; Almardini W Read publication 2019 BMJ Case Reports
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized double-blind, placebo-controlled proof-of-concept study Vortioxetine Biederman J, Lindsten A, Sluth L B, Petersen M L, Ettrup A, Eriksen H-L F, Fava M Read publication 2019 Journal of Psychopharmacology
Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study. Vortioxetine Cormack F, McCue M, Taptiklis N, Skirrow C, Glazer E, Panagopoulos E, van Schaik TA, Fehnert B, King J, Barnett JH Read publication 2019 JMIR Mental Health